RxDoctor Payments Data

Sha-Rhonda Morton, DO

Family Medicine · Tulsa, OKNPI 1528202991

Payments from drug & device makers

$931in general payments, 2019–2025

Across 36 payments — averaging $25.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$311
  • Teva Pharmaceuticals USA, Inc.$130
  • Pfizer$65
  • Exact Sciences$49
  • GSK$48
  • AstraZeneca$46
  • plus $282 from 13 others

What the payments were for

  • Food & beverage$931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$931 in reported general payments places this provider in the 60th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$534
Medicare patients
17
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$17,220
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,213
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,486
Breo ElliptaFluticasone/Vilanterol14$6,181
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,514
Albuterol Sulfate HfaAlbuterol Sulfate68$2,054
Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid11$1,560
Rosuvastatin Calcium94$1,334
Gabapentin74$1,320
Diclofenac Sodium12$1,207
Cyclobenzaprine Hcl73$1,040
Atorvastatin Calcium92$790
Omeprazole41$725
Ibuprofen43$646
Amlodipine Besylate103$633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$48$23,39436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →